Supernus Pharmaceuticals Inc
NASDAQ:SUPN
| Market Cap (Intraday) | 1.90B |
| Current PE | 30.73 |
| Forward PE | 16.49 |
| 2yr Forward PE | 13.26 |
| 10-Day MA | $32.37 |
| 50-Day MA | $32.02 |
| 200-Day MA | $34.17 |
Supernus Pharmaceuticals Inc Stock, NASDAQ:SUPN
9715 Key West Avenue, Rockville, Maryland 20850
United States of America
Phone: +1.301.838.2500
Number of Employees: 674
Description
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.